drugset
drugset / Trial / NCT04052971

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

NCT04052971 ↗

Phase 1 Completed 24 enrolled Abion Inc Novotech (Australia) Pty Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a dose escalation, Phase 1 study of ABN401 in patients with advanced solid tumors, refractory metastatic disease, or refractory locally advanced disease not amenable to local therapy.

Timeline

Start
2019-08-01
Primary completion
2023-11-30
Completion
2024-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ABN401 Unknown 50 mg Oral
Subject ABN401 Unknown 800 mg Oral
Subject ABN401 Unknown 1800 mg Oral

Indications

cancer